COMMERCIAL ENTRY: LOWER-LIMB CTO

Flux Robotics is focused on complex lower-limb Chronic Total Occlusion (CTO) in CLTI patients as its initial commercial beachhead. We collaborate with leading hospitals and regulatory partners to validate staged clinical expansion.

Clinical & Strategic Partners

COMPLEX LOWER-LIMB CTO (CLTI)

Chronic limb-threatening ischemia affects millions of patients globally. CTO crossing remains the primary technical bottleneck in these procedures.
Flux enables controlled true-lumen navigation, addressing the core unmet need in CTO interventions.

a group of doctors performing surgery on a patient

a group of doctors performing surgery on a patient

BEACHHEAD INDICATION

REGULATORY STRATEGY

We follow a staged validation approach:

Pre-clinical in-vivo feasibility
GLP validation
First-in-Human CTO study.

This de-risks regulatory entry while building clinical evidence in a high-value indication.

person holding silver and black hand tool

person holding silver and black hand tool

STAGED VALIDATION

PLATFORM EXPANSION STRATEGY

Following CTO commercialization, the Flux magnetic navigation platform expands into fenestration and complex cannulation workflows.

One platform. Multiple high-value vascular indications.

THE FLUX FUTURE

LET'S BUILD THE FUTURE TOGETHER

Get in contact with us to book a demo and explore opportunities.